methylphenidate patch (Daytrana)

Pharmacy Author:
Medical and Pharmacy Editor:

GENERIC NAME: methylphenidate patch

BRAND NAME: Daytrana

DRUG CLASS AND MECHANISM: Methylphenidate is a medication used for treating attention deficit hyperactivity disorder (ADHD). It stimulates the central nervous system (CNS or brain) in a manner that is similar to amphetamines; however, its actions are milder than amphetamines. Amphetamines stimulate the brain by increasing the level of neurotransmitters, dopamine and norepinephrine, in the brain (neurotransmitters are chemicals produced by nerves that are released and attach to other nearby nerves as a means of communication among nerves). The exact mechanism of action of the drug in people with ADHD is unknown. Methylphenidate is the active ingredient in methylphenidate (Ritalin, Concerta), and also is available as pills and liquids. The FDA approved Methylphenidate patches in April 2006.

PRESCRIPTION: Yes

GENERIC AVAILABLE: No

PREPARATIONS: Patch: 10 mg, 15 mg, 20 mg, and 30 mg strengths, delivering doses over 9 hours.

STORAGE: Store Methylphenidate patches between temperatures of 15 C and 30 C (59 F and 86 F). Do not store patches unpouched (outside of their container). Do not store patches in refrigerators or freezers. Once the sealed tray or outer pouch is opened, use contents within 2 months.

PRESCRIBED FOR: Methylphenidate transdermal patches are used for the treatment of attention deficit hyperactivity disorder (ADHD).

DOSING: The recommended dose for methylphenidate patches is to apply one 10 mg patch once daily for 9 hours for week 1, then increase to 15 mg patch for week 2, then increase to 20 mg patch for week 3, then increase to 30 mg patch for week 4 depending on response. The patch is applied to the hip area 2 hours before the effect is needed, and removed 9 hours after application. The dosing is for children aged 6 to 17.

DRUG INTERACTIONS: Methylphenidate should not be combined with monoamine oxidase inhibitors (MAOIs) such as phenelzine (Nardil), selegiline (Zelapar, Emsam, and Eldepryl), tranylcypromine (Parnate), procarbazine (Matulane), rasagiline (Azilect), and isocarboxazid (Marplan) because of risks of hypertensive crisis. Use of methylphenidate and MAO inhibitors should be separated by at least 14 days.

PREGNANCY: There are no adequate studies done on Methylphenidate to determine safe and effective use in pregnant women.

NURSING MOTHERS: It is not known whether methylphenidate enters breast milk; therefore, it is best to be cautious before using it in nursing mothers.

SIDE EFFECTS: Side effects of methylphenidate are decreased appetite, sleeplessness, allergic contact dermatitis, nausea, vomiting, weight loss, dizziness, abdominal pain, emotional instability, and anorexia.

Methylphenidate may be abused and it is a Schedule II controlled medication. Long-term abuse can cause tolerance, psychological dependence, abnormal behavior, and psychosis. Use cautiously in people with a history of drug or alcohol abuse.

REFERENCE: FDA Prescribing Information.


Medically Reviewed by a Doctor on 7/24/2014



Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.


Back to Medications Index